地高辛作为抗肿瘤候选药物的相关研究进展

Research progress of digoxin as an anti-tumor candidate drug

地高辛是目前强心苷类药物中使用时间最悠久,使用最广泛的药物。近年来随着老药新用研究的不断深入,地高辛的抗肿瘤作用已成为研究的热点。地高辛能够通过抑制人类肿瘤细胞的增殖以及诱导肿瘤细胞凋亡,发挥抗肿瘤作用,与其他抗肿瘤药物联合应用时亦能发挥协同增敏作用。其作用主要涉及抑制Na+/K+-ATP酶和缺氧诱导因子-1α的表达。但地高辛会引起严重不良反应,因此在关注抗肿瘤作用的同时,需重视其有效浓度和药物相互作用等问题。

Digoxin is the oldest and most widely used drug among cardiac glycosides currently. In recent years,with the continuous deepening of research on new use of old drugs, the anti-tumor effect of digoxin has become a hot spot. Digoxin can play an anti-tumor role by inhibiting the proliferation of human tumor cells and inducing the apoptosis of tumor cells, and it can also play synergistic sensitization effect when combined with other anti-tumor drugs. The target of action is to inhibit the expression of Na+/K+-ATPase and hypoxia-inducible factor-1α. However, digoxin can cause serious adverse reactions. So it is necessary to consider the drug effective concentration and drug interaction while paying attention to its anti-tumor effect.